IntraBio is a late-stage biopharmaceutical company developing novel therapies for rare (“orphan”) and common neurodegenerative diseases
Joined November 2018
- Tweets 31
- Following 11
- Followers 89
- Likes 3
Photos and videos
IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort businesswire.com/news/home/2…
2
233
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)
accesswire.com/660477/IntraB…
IntraBio Appoints Jim Meyers as President and CEO
accesswire.com/618176/IntraB…
1
Professor Michael Strupp Receives the 2020 Galenus-von-Pergamon Award
accesswire.com/viewarticle.a…
IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…
New hope for Treatment Against Niemann-Pick disease Type C businessnewstribune.com/2020… via @Business News Tribune
"IntraBio Reports Positive Data from NPC Study" - @GlobalGenes
globalgenes.org/2020/10/06/i…
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.a…
1
JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: bit.ly/2KYdOvD
#NPC #niemannpick #nnpdf
1
2
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease #IntraBio #Ataxia #FDA #Biotech
accesswire.com/538752/IntraB…
1
1
3
IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease #IntraBio #MHRA #NPC
accesswire.com/538583/IntraB…
2
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease #Biotech #FDA #IntraBio #IND
accesswire.com/535211/IntraB…
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease #Biotech #FDA #IntraBio
accesswire.com/534958/IntraB…
1
1
IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 #RareDisease #Biotech #IntraBio
accesswire.com/532110/IntraB…
IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 #RareDisease #FDA #Biotech #IntraBio
accesswire.com/530834/IntraB…
IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA #RareDisease #Biotech #IntraBio
accesswire.com/530328/IntraB…
1
1
RareDaily reports on our recent Rare Pediatric Disease Designation for Niemann-Pick disease Type C for our lead compound series
globalgenes.org/raredaily/fd… via @GlobalGenes
2
IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA #IntraBio #Ataxia #RareDisease #Biotech
accesswire.com/530119/IntraB…
1
IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of Spinocerebellar Ataxia #RareDisease #Ataxia #IntraBio
accesswire.com/529750/IntraB…
IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series #RareDisease #OrphanDisease #Biotech #NiemannPick #FDA #IntraBio
accesswire.com/529563/IntraB…